Illumina has announced that Charles Dadswell has stepped down as general counsel and corporate secretary.
According to the DNA sequencing company, Dadswell has agreed to remain an Illumina employee as an adviser to CEO Jacob Thaysen and the board until March 31, 2025. The company has appointed Scott Davies as acting general counsel and secretary while it carries out a search for Dadswell’s permanent successor.
According to his LinkedIn profile, Dadswell joined Illumina in 2013 having previously been vice president, general counsel for the Americas and corporate director for global intellectual property (IP) at bioMéerieux. Before that he was general counsel at BioDelivery Sciences, having previously spent 14 years at GlaxoSmithKline (now GSK) as vice president for US IP.
He did not respond immediately to a request for comment.
Before taking on his interim position, Davies was Illumina’s vice president for legal, chief corporate counsel and assistant secretary. He joined the company in 2009 and has since taken on positions of increasing responsibility.
Davies was previously of counsel with law firm Gibson Dunn & Crutcher, where his practice included corporate governance, securities, M&A, capital markets, finance and private equity. He was earlier an attorney with Allen & Overy in London.
Thaysen says in a statement: ‘Throughout his tenure, [Charles] has been a valuable adviser to Illumina’s leadership team and its board of directors. He is a respected industry leader whose expertise and advice helped [the company] reach the industry leadership role it holds today. I want to personally thank [him] for his advice and assistance as I was joining Illumina. I speak for everyone at [the company] when I say how appreciative we are of his many contributions to our organization.’
Dadswell says in a statement issued by the company: ‘I’ve watched and been a part of Illumina growing from a start-up to one of the most important and innovative companies in the world, and I’m proud to have been a part of that journey.’